Literature DB >> 25933967

The pharmacokinetic interaction between levofloxacin and sunitinib.

Andrzej Czyrski1, Katarzyna Kondys2, Edyta Szałek3, Agnieszka Karbownik3, Edmund Grześkowiak3.   

Abstract

BACKGROUND: The aim of this study was to evaluate the impact of sunitinib on pharmacokinetics of levofloxacin. The previous study proved that levofloxacin co-administered with sunitib changes the following pharmacokinetic parameters i.e. Cmax and AUC for both sunitinib and SU012662 (sunitinib metabolite). We will also investigate if the limited sample strategy can be applied for levofloxacin.
METHODS: Rabbits were divided into two groups. In both groups there were six animals. In the control group levofloxacin was administered and in investigated group levofloxacin and sunitinib were co-administered. The dose of levofloxacin was 20mg/kg and the dose of sunitinib was 25mg. The concentration in plasma was determined by HPLC-FLD. The pharmacokinetic parameters were evaluated by WinNonLin software. The results were evaluated by the following statistical tests: Shapiro-Wilk, t-Student and Mann-Whitney test.
RESULTS: Pharmacokinetics of levofloxacin obeys the two-compartment model. Sunitinib influences the following pharmacokinetic parameters of levofloxacin: half-life, elimination constant and volume of distribution. Statistical analysis proved that there is a correlation between AUC and the following five time-points: 0.25 h, 4h, 6h, 10h and 12h.
CONCLUSIONS: The study proved that there is a potential pharmacokinetic interaction between sunitinib and levofloxacin. The statistical analysis proved that the limited sample strategy can be applied for levofloxacin.
Copyright © 2015 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier Urban & Partner Sp. z o.o. All rights reserved.

Entities:  

Keywords:  Interaction; Levofloxacin; Limited sample strategy; Sunitinib

Mesh:

Substances:

Year:  2014        PMID: 25933967     DOI: 10.1016/j.pharep.2014.12.013

Source DB:  PubMed          Journal:  Pharmacol Rep        ISSN: 1734-1140            Impact factor:   3.024


  5 in total

1.  A Potent In Vivo Antitumor Efficacy of Novel Recombinant Type I Interferon.

Authors:  Kang-Jian Zhang; Xiao-Fei Yin; Yuan-Qin Yang; Hui-Ling Li; Yan-Ni Xu; Lie-Yang Chen; Xi-Jun Liu; Su-Jing Yuan; Xian-Long Fang; Jing Xiao; Shuai Wu; Hai-Neng Xu; Liang Chu; Kanstantsin V Katlinski; Yuliya V Katlinskaya; Rong-Bing Guo; Guang-Wen Wei; Da-Cheng Wang; Xin-Yuan Liu; Serge Y Fuchs
Journal:  Clin Cancer Res       Date:  2016-09-28       Impact factor: 12.531

2.  The degradation of levofloxacin in infusions exposed to daylight with an identification of a degradation product with HPLC-MS.

Authors:  Andrzej Czyrski; Katarzyna Anusiak; Artur Teżyk
Journal:  Sci Rep       Date:  2019-03-06       Impact factor: 4.379

3.  The application of Box-Behnken-Design in the optimization of HPLC separation of fluoroquinolones.

Authors:  Andrzej Czyrski; Justyna Sznura
Journal:  Sci Rep       Date:  2019-12-19       Impact factor: 4.379

4.  A Systematic Review of Multiple Linear Regression-Based Limited Sampling Strategies for Mycophenolic Acid Area Under the Concentration-Time Curve Estimation.

Authors:  Joanna Sobiak; Matylda Resztak
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2021-09-04       Impact factor: 2.441

5.  The Evaluation of Multiple Linear Regression-Based Limited Sampling Strategies for Mycophenolic Acid in Children with Nephrotic Syndrome.

Authors:  Joanna Sobiak; Matylda Resztak; Maria Chrzanowska; Jacek Zachwieja; Danuta Ostalska-Nowicka
Journal:  Molecules       Date:  2021-06-18       Impact factor: 4.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.